Japanese drug major Eisai (TYO: 4523) has entered into a settlement agreement with Indian drugmaker Glenmark Pharmaceuticals (BSE: 532296) and its US subsidiaries to resolve their patent litigation relating to Eisai's Banzel (rufinamide) in the USA.
As a result of the settlement, or pay-for-delay deal, Glenmark will be permitted to market a generic version of Banzel in the USA on May 30, 2022, or potentially earlier under certain circumstances. Additional terms of the settlement agreement are confidential.
Banzel is an anti-epileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged one year and older and adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze